NeuroBo Pharmaceuticals’ first lead candidate, NB-01, is positioned as a potential treatment for diabetic neuropathic pain. The candidate, which in 2018 will move into a phase III clinical trial, uses extracts of two species of the plant genus Dioscorea, used in traditional medicine for centuries, but never yet subject to systematic study. We caught up with NeuroBo’s Mark Versavel and Nandan Padukone to find out more.
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners recently announced the launch of Magnolia Neurosciences Corporation – a biopharmaceutical company advancing a new class of neuroprotective medicines.Read More
We recently spoke to Dr. Hervé Perron, HDR, Chief Scientific Officer at GeNeuro to learn about their progress developing new treatments for neurological and autoimmune diseases associated with pathogenic proteins expressed by human endogenous retroviruses (HERVs).Read More
The first functional stem-cell derived neuromuscular junction model has recently been licensed, which could help the quest to develop new drugs to treat associated neurodegenerative diseases. We caught up with James Hickman, CSO, Hesperos, to learn more about the model, and some of the benefits it brings.Read More